FDA Grants Rare Pediatric Disease Designation to LSTA1 in Osteosarcoma

LSTA1 has received rare pediatric disease designation from the FDA for the treatment of patients with osteosarcoma.

Related Keywords

United States ,Gastroenterol Hepatol ,Research Development ,European Medicines Agency ,Lisata Therapeutics Inc ,Lisata Therapeutics ,Lancet Gastroenterology ,Orphan Medical Products ,Lsta1 ,Patients With Osteosarcoma ,Kristenk Buck ,D ,